Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced a second commercial agreement with Weill Cornell Medicine to integrate its Nociscan platform into a groundbreaking clinical trial. The study, led by renowned neurosurgeon Roger Härtl, MD, will evaluate the long-term effects of lumbar microdiscectomy surgery with and without intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes, disc health, and pain biomarkers over two years.
The trial, titled "Bone Marrow Aspirate Concentrate Injection with MRI's – a Prospective Randomized Controlled Trial" (IRB Protocol No. 24-09027977), aims to provide deeper insights into degenerative disc disease (DDD), a condition affecting approximately 266 million people worldwide. Dr. Härtl, founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center, emphasized the study's potential: "This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging."
Nociscan, Aclarion's evidence-supported SaaS platform, noninvasively helps physicians distinguish between painful and nonpainful discs by quantifying chemical biomarkers from magnetic resonance spectroscopy (MRS) data. When used with other diagnostic tools, Nociscan provides critical insights into the location of chronic low back pain, demonstrating a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated. This marks the second trial at Weill Cornell Medicine to incorporate Nociscan, following a previous agreement.
Ryan Bond, Chief Strategy Officer of Aclarion, expressed enthusiasm for the collaboration: "Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan."
The study is expected to inform future treatments for DDD by exploring the natural history of the disease and the role of BMAC injections. The use of Nociscan allows researchers to measure pain biomarkers that are not available through traditional imaging, potentially leading to more targeted and effective therapies.
Aclarion continues to expand the reach of its Nociscan platform through research partnerships and commercial agreements. For more information about the company and its technology, visit www.aclarion.com. To find a Nociscan center, view the site map here. The latest news and updates about Aclarion are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
